Trial Profile
A Multi-center, Open, Randomized, Parallel-group Study to Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2019
Price :
$35
*
At a glance
- Drugs Glimepiride/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Handok Inc
- 02 May 2018 Primary endpoint of compliance of patients treated with once-daily or twice-daily has been met, according to results published in the Clinical Therapeutics.
- 02 May 2018 Results published in the Clinical Therapeutics
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association